Exantas Capital Corp. Reports Results For Three Months And Year Ended December 31, 2019
NEW YORK, March 3, 2020 /PRNewswire/ -- Exantas Capital Corp. (NYSE: XAN) ("XAN" or the "Company") reports results for the three months and year ended December 31, 2019.
Significant Items and Highlights
- GAAP net income allocable to common shares was $0.12 per share-diluted for the three months ended December 31, 2019, including $(0.10) per share-diluted of negative fair value adjustments discussed below.
- Core Earnings were $0.23 per common share-diluted for the three months ended December 31, 2019 (see Schedule I).
- Management anticipates the Company will declare a cash dividend of $0.275 per share on its common stock for the first quarter of 2020, which would be a 37.5% increase over the first quarter of 2019 dividend of $0.20 per share.
- XAN originated or acquired $203.0 million and $942.0 million of new commercial real estate ("CRE") loans during the three months and year ended December 31, 2019, respectively (see Schedule III).
- On February 24, 2020, XAN announced the expansion of its CRE debt platform to include fixed-rate CRE loans through its integration of C-III Commercial Mortgage LLC into its Manager.
- GAAP book value was $14.00 per common share at December 31, 2019 as compared to $14.02 per common share at December 31, 2018.
- Economic book value, which adjusts for the face redemption amounts of the Company's outstanding preferred stock and convertible senior notes, was $13.61 per common share at December 31, 2019, up from $13.54 per common share at December 31, 2018 (see Schedule IV).
- XAN priced a CRE debt securitization on March 2, 2020 that will finance CRE loans of $522.6 million at a weighted average cost of the one-month London Interbank Offered Rate ("LIBOR") plus 1.43%. The Company intends to purchase $26.1 million and $16.3 million of the Class D notes and Class E notes, respectively, upon close.
Three Months and Year Ended December 31, 2019 Results
- GAAP net income allocable to common shares was $3.8 million, or $0.12 per share-diluted, and $25.6 million, or $0.81 per share-diluted, for the three months and year ended December 31, 2019, respectively, as compared to GAAP net income allocable to common shares of $7.4 million, or $0.23 per share-diluted, and $7.0 million, or $0.22 per share-diluted, for the three months and year ended December 31, 2018, respectively.
- GAAP net income allocable to common shares for the three months ended December 31, 2019 includes approximately $(3.2) million, or $(0.10) per share-diluted, of fair value adjustments on the Company's remaining CRE asset held for sale.
- Core Earnings were $7.3 million, or $0.23 per common share-diluted, and $34.0 million, or $1.07 per common share-diluted, for the three months and year ended December 31, 2019, respectively, as compared to Core Earnings, adjusted of $7.5 million, or $0.24 per common share-diluted, and $22.3 million, or $0.71 per common share-diluted, for the three months and year ended December 31, 2018, respectively (see Schedule I).
- Common stock cash dividends of $0.275 and $0.95 per share were declared and paid for the three months and year ended December 31, 2019, respectively.
Additional Items
Commercial Real Estate
- Substantially all of XAN's $1.8 billion CRE loan portfolio comprised floating-rate senior whole loans at December 31, 2019.
- XAN's CRE floating-rate whole loan portfolio had a weighted average spread of 3.49% over the one-month LIBOR of 1.76% at December 31, 2019.
The following table summarizes XAN's CRE loan activities and fundings of previous commitments for the three months and years ended December 31, 2019 and 2018 (in millions, except percentages and amounts in footnotes):
Three Months December 31, |
Year Ended December 31, |
Three Months December 31, |
Year Ended December 31, |
|||||||||||||
New CRE loan commitments |
$ |
203.0 |
$ |
722.5 |
$ |
274.9 |
$ |
842.4 |
||||||||
New CRE preferred equity investments |
— |
8.7 |
— |
19.2 |
||||||||||||
Total CRE loan commitments and investments |
203.0 |
731.2 |
274.9 |
861.6 |
||||||||||||
Payoffs and paydowns (1)(2) |
(182.0) |
(643.2) |
(203.1) |
(575.6) |
||||||||||||
Previous commitments funded |
10.8 |
43.0 |
13.3 |
51.4 |
||||||||||||
New unfunded loan commitments and investments |
(13.6) |
(53.1) |
(30.5) |
(81.0) |
||||||||||||
Net CRE loans funded |
18.2 |
77.9 |
54.6 |
256.4 |
||||||||||||
Acquired CRE loans (committed balance) |
— |
210.8 |
— |
— |
||||||||||||
Payoffs and paydowns (1) |
(22.8) |
(39.6) |
— |
— |
||||||||||||
Previous commitments funded |
— |
0.2 |
— |
— |
||||||||||||
Acquired unfunded loan commitments |
— |
(14.0) |
— |
— |
||||||||||||
Net CRE loans (repaid) acquired |
(22.8) |
157.4 |
— |
— |
||||||||||||
Net CRE loans (repaid) funded and acquired |
$ |
(4.6) |
$ |
235.3 |
$ |
54.6 |
$ |
256.4 |
||||||||
Weighted average one-month LIBOR floor on new originations |
1.80 |
% |
2.17 |
% |
2.09 |
% |
1.86 |
% |
||||||||
Weighted average spread above one-month LIBOR (3) |
2.89 |
% |
3.31 |
% |
3.06 |
% |
3.39 |
% |
||||||||
Weighted average unlevered yield, including amortization of |
5.04 |
% |
5.72 |
% |
5.72 |
% |
5.83 |
% |
||||||||
(1) CRE loan payoffs and extensions resulted in exit and extension fees of $869,000 and $1.0 million during the three months ended December 31, 2019 and 2018, respectively, and $2.6 million and $3.0 million during the years ended December 31, 2019 and 2018, respectively. |
||||||||||||||||
(2) Activity excludes legacy CRE loans (see Strategic Plan Update). |
||||||||||||||||
(3) Applies to new floating-rate CRE whole loans funded and acquired. |
||||||||||||||||
Commercial Mortgage-Backed Securities
XAN's $582.1 million commercial mortgage-backed securities ("CMBS") portfolio, at par, had a carrying value of $520.7 million (due substantially to net purchase discounts) and a weighted average coupon of 4.30% at December 31, 2019.
The following table summarizes XAN's CMBS activities, at face value, for the three months and years ended December 31, 2019 and 2018 (in millions, except percentages):
Three Months December 31, |
Year Ended December 31, |
Three Months December 31, |
Year Ended December 31, |
|||||||||||||
CMBS acquisitions |
$ |
73.0 |
$ |
147.2 |
$ |
83.2 |
$ |
252.3 |
||||||||
Sales |
— |
(0.6) |
(4.9) |
(14.9) |
||||||||||||
Principal paydowns |
(22.9) |
(56.4) |
(6.7) |
(20.9) |
||||||||||||
CMBS acquisitions, net |
$ |
50.1 |
$ |
90.2 |
$ |
71.6 |
$ |
216.5 |
||||||||
Weighted average coupon at the respective period end (1) |
3.99 |
% |
4.22 |
% |
4.71 |
% |
4.57 |
% |
||||||||
(1) Applies to new CMBS acquired during the respective periods. |
||||||||||||||||
Commercial Real Estate Securitizations
- XAN priced a CRE debt securitization on March 2, 2020 that will finance CRE loans of $522.6 million and issue $435.7 million of non-recourse, floating-rate notes, of which $393.3 million will be sold to third parties at a weighted average cost of one-month LIBOR plus 1.30%. The Company intends to purchase $26.1 million and $16.3 million of the Class D notes and Class E notes, respectively, rated BBB(high)(sf) and BBB(low)(sf), respectively, upon close.
Liquidity
- At February 28, 2020, XAN had available liquidity of $138.7 million from two primary sources:
- unrestricted cash and cash equivalents of $70.2 million; and
- approximately $68.5 million from available financing of unlevered CRE loans and CMBS.
- In January 2020, the 8.00% convertible senior notes due 2020 were paid off upon maturity.
Common Stock Book Value, Economic Book Value and Total Stockholders' Equity
The following table rolls forward XAN's common stock book value from September 30, 2019 to December 31, 2019 and reconciles common stock book value to economic book value (a non-GAAP measure) at December 31, 2019 (see Schedule IV) (in thousands, except per share data and amounts in footnotes):
Total Amount |
Per Share Amount |
|||||||
Common stock book value at September 30, 2019 (1) |
$ |
444,070 |
$ |
14.12 |
||||
Net income allocable to common shares |
3,798 |
0.12 |
||||||
Change in other comprehensive income: |
||||||||
Available-for-sale securities |
(1,139) |
(0.04) |
||||||
Derivatives |
1,804 |
0.06 |
||||||
Common stock dividends |
(8,651) |
(0.28) |
||||||
Common stock dividends on unvested shares |
(116) |
— |
||||||
Accretion from additional shares outstanding at December 31, 2019 (2) |
676 |
0.02 |
||||||
Total net decrease |
(3,628) |
(0.12) |
||||||
Common stock book value at December 31, 2019 (1)(3) |
$ |
440,442 |
$ |
14.00 |
||||
Reconciling items in arriving at economic book value at December 31, 2019: |
||||||||
Non-cash convertible senior notes' unamortized discounts: |
||||||||
4.50% Convertible Senior Notes |
(8,133) |
(0.26) |
||||||
8.00% Convertible Senior Notes |
(6) |
— |
||||||
Series C Preferred Stock redemption value in excess of carrying value |
(4,045) |
(0.13) |
||||||
Economic book value at December 31, 2019 |
$ |
428,258 |
$ |
13.61 |
||||
(1) Per share calculations exclude unvested restricted stock, as disclosed on the consolidated balance sheets, of 420,962 and 424,164 shares at December 31, 2019 and September 30, 2019, respectively. The denominators for the calculations are 31,459,632 and 31,446,738 at December 31, 2019 and September 30, 2019, respectively. |
||||||||
(2) Per share amount calculations include 12,894 additional shares of restricted stock that vested during the three months ended December 31, 2019. |
||||||||
(3) Common stock book value is calculated as total stockholders' equity of $556.4 million less preferred stock equity of $116.0 million at December 31, 2019. |
||||||||
The following table presents the economic book value per common share at the dates presented:
At December 31, 2019 |
At September 30, 2019 |
At June 30, 2019 |
At March 31, 2019 |
At December 31, 2018 |
||||||||||||||||
Economic book value |
$ |
13.61 |
$ |
13.71 |
$ |
13.63 |
$ |
13.60 |
$ |
13.54 |
||||||||||
Investment Portfolio
The following table summarizes the amortized cost and net carrying amount of XAN's investment portfolio at December 31, 2019, classified by asset type (in thousands, except percentages and amounts in footnotes):
At December 31, 2019 |
Amortized Cost |
Net Carrying |
Percent of |
Weighted |
||||||||||||
Core Assets: |
||||||||||||||||
CRE whole loans (1)(2) |
$ |
1,749,093 |
$ |
1,747,633 |
75.10 |
% |
5.52% |
|||||||||
CRE mezzanine loan and preferred equity investments (2) |
30,848 |
30,848 |
1.33 |
% |
11.18% |
|||||||||||
CMBS, fixed-rate (3) |
132,235 |
138,039 |
5.93 |
% |
4.10% |
|||||||||||
CMBS, floating-rate (3) |
382,659 |
382,675 |
16.44 |
% |
4.39% |
|||||||||||
Total Core Assets |
2,294,835 |
2,299,195 |
98.80 |
% |
||||||||||||
Non-Core Assets: |
||||||||||||||||
Legacy CRE assets (4)(5) |
35,539 |
28,004 |
1.20 |
% |
1.47% |
|||||||||||
Total Core and Non-Core Assets |
$ |
2,330,374 |
$ |
2,327,199 |
100.00 |
% |
||||||||||
(1) Net carrying amount includes an allowance for loan losses of $1.5 million at December 31, 2019. |
||||||||||||||||
(2) Classified as CRE loans on the consolidated balance sheet. |
||||||||||||||||
(3) Classified as investment securities available-for-sale on the consolidated balance sheet. |
||||||||||||||||
(4) Includes one legacy CRE loan with an amortized cost of $11.5 million classified as a CRE loan on the consolidated balance sheet as XAN intends to hold this loan to maturity. |
||||||||||||||||
(5) Net carrying amount includes a lower of cost or market value adjustment at December 31, 2019. |
||||||||||||||||
Strategic Plan Update
In November 2016, XAN's board of directors approved the strategic plan (the "Plan"). The Plan contemplated disposing of certain loans underwritten prior to 2010, exiting non-core businesses and investments and maintaining a dividend policy based on sustainable earnings. XAN has substantially completed the execution of the Plan.
In November 2019, XAN foreclosed on the remaining legacy CRE loan held for sale. The property is being marketed for sale and is classified as an asset held for sale on the consolidated balance sheet at December 31, 2019. At December 31, 2019, XAN had approximately $28.0 million remaining of the $480.1 million of identified Plan assets.
Supplemental Information
The following schedules of reconciliations and supplemental information at December 31, 2019 are included at the end of this release:
- Schedule I - Reconciliation of GAAP Net Income (Loss) to Core Earnings;
- Schedule II - Summary of Securitization Performance Statistics;
- Schedule III - CRE Loan Activities;
- Schedule IV - Economic Book Value Per Share; and
- Schedule V - Supplemental Information.
About Exantas Capital Corp.
Exantas Capital Corp. is a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and other commercial real estate-related debt investments.
The Company is externally managed by Exantas Capital Manager Inc. (the "Manager"), which is an indirect wholly-owned subsidiary of C-III Capital Partners LLC, a leading commercial real estate investment management and services company engaged in a broad range of activities.
For more information, please visit XAN's website at www.exantas.com or contact investor relations at [email protected].
Safe Harbor Statement
Statements made in this release may include forward-looking statements, which involve substantial risks and uncertainties. XAN's actual results, performance or achievements could differ materially from those expressed or implied in this release. The risks and uncertainties associated with forward-looking statements contained in this release include those related to:
- fluctuations in interest rates and related hedging activities;
- the availability of debt and equity capital to acquire and finance investments;
- defaults or bankruptcies by borrowers on XAN's loans or on loans underlying its investments;
- adverse market trends that have affected and may continue to affect the value of real estate and other assets underlying XAN's investments;
- increases in financing or administrative costs; and
- general business and economic conditions that have in the past impaired and may in the future impair the credit quality of borrowers and XAN's ability to originate loans.
For further information concerning these and other risks pertaining to the forward-looking statements contained in this release, and to the general risks to which XAN is subject, see Item 1A, "Risk Factors," included in its most recent Annual Report on Form 10-K and the risks expressed in its other public filings with the Securities and Exchange Commission (the "SEC").
XAN cautions you not to place undue reliance on any forward-looking statements contained in this release, which speak only as of the date of this release. All subsequent written and oral forward-looking statements attributable to XAN or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this release. Except to the extent required by applicable law or regulation, XAN undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.
Furthermore, certain non-GAAP financial measures are discussed in this release. XAN's presentation of this information is not intended to be considered in isolation of or as a substitute for the financial information presented in accordance with GAAP. Reconciliations of these non-GAAP financial measures to the most comparable measures prepared in accordance with GAAP are set forth in Schedule I and Schedule IV of this release and can be accessed through XAN's filings with the SEC at www.sec.gov.
The remainder of this release contains XAN's unaudited (2019) and audited (2018) consolidated balance sheets, unaudited (fourth quarter ended 2019 and 2018 and year ended 2019) and audited (year ended 2018) consolidated statements of operations, a reconciliation of GAAP net income (loss) to Core Earnings, a summary of securitization performance statistics, a summary of XAN's CRE loan activities, a reconciliation of XAN's common stock book value to its economic book value and supplemental information regarding XAN's CRE loan portfolio.
EXANTAS CAPITAL CORP. AND SUBSIDIARIES |
||||||||
CONSOLIDATED BALANCE SHEETS |
||||||||
(in thousands, except share and per share data) |
||||||||
December 31, |
||||||||
2019 |
2018 |
|||||||
(unaudited) |
||||||||
ASSETS (1) |
||||||||
Cash and cash equivalents |
$ |
79,958 |
$ |
82,816 |
||||
Restricted cash |
14,476 |
12,658 |
||||||
Accrued interest receivable |
8,042 |
8,198 |
||||||
CRE loans, net of allowances of $1,460 and $1,401 |
1,789,985 |
1,551,967 |
||||||
Investment securities available-for-sale |
520,714 |
418,998 |
||||||
Principal paydowns receivable |
19,517 |
32,083 |
||||||
Investments in unconsolidated entities |
1,548 |
1,548 |
||||||
Derivatives, at fair value |
30 |
985 |
||||||
Other assets |
3,290 |
4,015 |
||||||
Assets held for sale |
16,766 |
17,645 |
||||||
Total assets |
$ |
2,454,326 |
$ |
2,130,913 |
||||
LIABILITIES (2) |
||||||||
Accounts payable and other liabilities |
$ |
3,408 |
$ |
7,550 |
||||
Management fee payable |
701 |
938 |
||||||
Accrued interest payable |
4,408 |
4,224 |
||||||
Borrowings |
1,872,577 |
1,554,223 |
||||||
Distributions payable |
10,492 |
7,265 |
||||||
Derivatives, at fair value |
4,558 |
1,043 |
||||||
Accrued tax liability |
38 |
31 |
||||||
Liabilities held for sale |
1,746 |
1,820 |
||||||
Total liabilities |
1,897,928 |
1,577,094 |
||||||
STOCKHOLDERS' EQUITY |
||||||||
Preferred stock, par value $0.001: 10,000,000 shares authorized 8.625% Fixed-to- |
5 |
5 |
||||||
Common stock, par value $0.001: 125,000,000 shares authorized; 31,880,594 and |
32 |
32 |
||||||
Additional paid-in capital |
1,085,041 |
1,082,677 |
||||||
Accumulated other comprehensive income (loss) |
1,821 |
(3,057) |
||||||
Distributions in excess of earnings |
(530,501) |
(525,838) |
||||||
Total stockholders' equity |
556,398 |
553,819 |
||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ |
2,454,326 |
$ |
2,130,913 |
||||
EXANTAS CAPITAL CORP. AND SUBSIDIARIES |
||||||||
CONSOLIDATED BALANCE SHEETS - (Continued) |
||||||||
(in thousands, except share and per share data) |
||||||||
December 31, |
||||||||
2019 |
2018 |
|||||||
(unaudited) |
||||||||
(1) Assets of consolidated variable interest entities ("VIEs") included in total assets |
||||||||
Restricted cash |
$ |
532 |
$ |
6,189 |
||||
Accrued interest receivable |
3,780 |
3,548 |
||||||
CRE loans, pledged as collateral |
957,045 |
700,986 |
||||||
Principal paydowns receivable |
19,239 |
31,914 |
||||||
Other assets |
25 |
157 |
||||||
Total assets of consolidated VIEs |
$ |
980,621 |
$ |
742,794 |
||||
(2) Liabilities of consolidated VIEs included in total liabilities above: |
||||||||
Accounts payable and other liabilities |
$ |
175 |
$ |
75 |
||||
Accrued interest payable |
897 |
709 |
||||||
Borrowings |
746,439 |
501,045 |
||||||
Total liabilities of consolidated VIEs |
$ |
747,511 |
$ |
501,829 |
||||
EXANTAS CAPITAL CORP. AND SUBSIDIARIES |
||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||
(in thousands, except share and per share data) |
||||||||||||||||
(unaudited) |
||||||||||||||||
For the Three Months Ended |
For the Year Ended |
|||||||||||||||
December 31, |
December 31, |
|||||||||||||||
2019 |
2018 |
2019 |
2018 |
|||||||||||||
(unaudited) |
(unaudited) |
(unaudited) |
||||||||||||||
REVENUES |
||||||||||||||||
Interest income: |
||||||||||||||||
CRE loans |
$ |
27,771 |
$ |
29,486 |
$ |
118,060 |
$ |
103,800 |
||||||||
Securities |
6,628 |
5,722 |
26,190 |
18,600 |
||||||||||||
Other |
125 |
118 |
636 |
379 |
||||||||||||
Total interest income |
34,524 |
35,326 |
144,886 |
122,779 |
||||||||||||
Interest expense |
20,149 |
19,751 |
83,837 |
67,616 |
||||||||||||
Net interest income |
14,375 |
15,575 |
61,049 |
55,163 |
||||||||||||
Other revenue |
24 |
38 |
101 |
120 |
||||||||||||
Total revenues |
14,399 |
15,613 |
61,150 |
55,283 |
||||||||||||
OPERATING EXPENSES |
||||||||||||||||
Management fees |
2,092 |
2,812 |
8,954 |
11,250 |
||||||||||||
Equity compensation |
565 |
334 |
2,212 |
2,717 |
||||||||||||
General and administrative |
3,234 |
2,723 |
10,392 |
10,666 |
||||||||||||
Depreciation and amortization |
8 |
9 |
47 |
77 |
||||||||||||
Impairment losses |
— |
934 |
— |
934 |
||||||||||||
(Recovery of) provision for loan losses, net |
— |
(335) |
58 |
(1,595) |
||||||||||||
Total operating expenses |
5,899 |
6,477 |
21,663 |
24,049 |
||||||||||||
8,500 |
9,136 |
39,487 |
31,234 |
|||||||||||||
OTHER INCOME (EXPENSE) |
||||||||||||||||
Equity in (losses) earnings of unconsolidated entities |
— |
(14) |
— |
217 |
||||||||||||
Net realized and unrealized gain on investment securities available- |
— |
70 |
4 |
639 |
||||||||||||
Net realized and unrealized gain on investment securities, trading |
— |
— |
— |
53 |
||||||||||||
Fair value adjustments on financial assets held for sale |
(3,225) |
(932) |
(4,682) |
(7,176) |
||||||||||||
Other income |
1,149 |
1,422 |
1,408 |
1,996 |
||||||||||||
Total other (expense) income |
(2,076) |
546 |
(3,270) |
(4,271) |
||||||||||||
INCOME FROM CONTINUING OPERATIONS BEFORE TAXES |
6,424 |
9,682 |
36,217 |
26,963 |
||||||||||||
Income tax benefit |
— |
312 |
— |
343 |
||||||||||||
NET INCOME FROM CONTINUING OPERATIONS |
6,424 |
9,994 |
36,217 |
27,306 |
||||||||||||
NET (LOSS) INCOME FROM DISCONTINUED OPERATIONS, |
(39) |
(40) |
(251) |
121 |
||||||||||||
NET INCOME |
6,385 |
9,954 |
35,966 |
27,427 |
||||||||||||
Net income allocated to preferred shares |
(2,587) |
(2,587) |
(10,350) |
(12,972) |
||||||||||||
Consideration paid in excess of carrying value of preferred shares |
— |
— |
— |
(7,482) |
||||||||||||
NET INCOME ALLOCABLE TO COMMON SHARES |
$ |
3,798 |
$ |
7,367 |
$ |
25,616 |
$ |
6,973 |
||||||||
NET INCOME PER COMMON SHARE - BASIC: |
||||||||||||||||
CONTINUING OPERATIONS |
$ |
0.12 |
$ |
0.24 |
$ |
0.82 |
$ |
0.22 |
||||||||
DISCONTINUED OPERATIONS |
— |
— |
— |
— |
||||||||||||
TOTAL NET INCOME PER COMMON SHARE - BASIC |
$ |
0.12 |
$ |
0.24 |
$ |
0.82 |
$ |
0.22 |
||||||||
NET INCOME PER COMMON SHARE - DILUTED: |
||||||||||||||||
CONTINUING OPERATIONS |
$ |
0.12 |
$ |
0.23 |
$ |
0.81 |
$ |
0.22 |
||||||||
DISCONTINUED OPERATIONS |
— |
— |
— |
— |
||||||||||||
TOTAL NET INCOME PER COMMON SHARE - DILUTED |
$ |
0.12 |
$ |
0.23 |
$ |
0.81 |
$ |
0.22 |
||||||||
WEIGHTED AVERAGE NUMBER OF COMMON SHARES |
31,456,377 |
31,234,840 |
31,430,113 |
31,198,319 |
||||||||||||
WEIGHTED AVERAGE NUMBER OF COMMON SHARES |
31,778,121 |
31,545,173 |
31,670,356 |
31,383,102 |
||||||||||||
SCHEDULE I
EXANTAS CAPITAL CORP. AND SUBSIDIARIES
RECONCILIATION OF GAAP NET INCOME (LOSS) TO CORE EARNINGS
(unaudited)
Core Earnings is a non-GAAP financial measure that XAN uses to evaluate its operating performance.
Core Earnings exclude the effects of certain transactions and GAAP adjustments that XAN believes are not indicative of its current CRE loan portfolio and other CRE-related investments and operations. Core Earnings exclude income (loss) from all non-core assets, such as commercial finance, middle market lending, residential mortgage lending, certain legacy CRE assets and other non-CRE assets designated as assets held for sale at the initial measurement date of December 31, 2016.
Core Earnings, for reporting purposes, is defined as GAAP net income (loss) allocable to common shares, excluding (i) non-cash equity compensation expense, (ii) unrealized gains and losses, (iii) non-cash provisions for loan losses, (iv) non-cash impairments on securities, (v) non-cash amortization of discounts or premiums associated with borrowings, (vi) net income or loss from a limited partnership interest owned at the initial measurement date, (vii) net income or loss from non-core assets,(1)(2) (viii) real estate depreciation and amortization, (ix) foreign currency gains or losses and (x) income or loss from discontinued operations. Core Earnings may also be adjusted periodically to exclude certain one-time events pursuant to changes in GAAP and certain non-cash items.
Although pursuant to the Third Amended and Restated Management Agreement XAN calculates incentive compensation using Core Earnings that exclude incentive compensation payable to the Manager, XAN includes incentive compensation payable to the Manager in calculating Core Earnings for reporting purposes.
Core Earnings allocable to common shares, adjusted ("Core Earnings Adjusted") is a non-GAAP financial measure used to evaluate XAN's operating performance. Core Earnings Adjusted exclude certain non-recurring items and the results of certain transactions that are not indicative of XAN's ongoing operating performance.
Core Earnings and Core Earnings Adjusted do not represent net income or cash generated from operating activities and should not be considered as an alternative to GAAP net income or as measures of liquidity under GAAP. XAN's methodology for calculating Core Earnings and Core Earnings Adjusted may differ from methodologies used by other companies to calculate similar supplemental performance measures, and, accordingly, its reported Core Earnings and Core Earnings Adjusted may not be comparable to similar performance measures used by other companies.
The following table provides a reconciliation from GAAP net income allocable to common shares to Core Earnings allocable to common shares and Core Earnings allocable to common shares, adjusted for the periods presented (in thousands, except per share data and the amounts in the footnotes):
For the Three Months Ended |
For the Year Ended |
|||||||||||||||
December 31, |
December 31, |
|||||||||||||||
2019 |
2018 |
2019 |
2018 |
|||||||||||||
Net income allocable to common shares - GAAP |
$ |
3,798 |
$ |
7,367 |
$ |
25,616 |
$ |
6,973 |
||||||||
Adjustment for realized gains on CRE assets (3) |
— |
(70) |
— |
(520) |
||||||||||||
Net income allocable to common shares - GAAP, adjusted |
3,798 |
7,297 |
25,616 |
6,453 |
||||||||||||
Reconciling items from continuing operations: |
||||||||||||||||
Non-cash equity compensation expense |
565 |
334 |
2,212 |
2,717 |
||||||||||||
Non-cash (recovery of) provision for CRE loan losses |
— |
(335) |
58 |
(1,427) |
||||||||||||
Litigation settlement expense (4) |
— |
— |
— |
(2,167) |
||||||||||||
Non-cash amortization of discounts or premiums associated with |
735 |
780 |
2,842 |
3,169 |
||||||||||||
Income tax benefit from non-core investments (1)(2) |
— |
(312) |
— |
(343) |
||||||||||||
Net realized gain on non-core assets (1)(2) |
— |
(1,449) |
(123) |
(1,925) |
||||||||||||
Net income from non-core assets (2) |
(895) |
(3) |
(871) |
(12) |
||||||||||||
Reconciling items from discontinued operations and CRE assets: |
||||||||||||||||
Net interest income on legacy CRE loans |
(161) |
(843) |
(747) |
(1,856) |
||||||||||||
Realized gain on liquidation of CRE loans |
— |
— |
— |
(1,000) |
||||||||||||
Operating expenses on legacy CRE loans |
— |
— |
— |
187 |
||||||||||||
Fair value adjustments on legacy CRE assets |
3,268 |
964 |
4,725 |
7,224 |
||||||||||||
Net loss from other non-CRE investments held for sale |
— |
— |
— |
508 |
||||||||||||
Loss (income) from discontinued operations, net of taxes |
39 |
40 |
251 |
(121) |
||||||||||||
Core Earnings before realized gain (loss) on CRE assets |
7,349 |
6,473 |
33,963 |
11,407 |
||||||||||||
Adjustment for realized loss on CRE loan |
— |
— |
— |
(2,332) |
||||||||||||
Adjustment for realized gain on CRE-related investment |
— |
70 |
— |
352 |
||||||||||||
Core Earnings allocable to common shares |
7,349 |
6,543 |
33,963 |
9,427 |
||||||||||||
Reconciling items in arriving at Core Earnings allocable to common |
||||||||||||||||
Realized loss on sale of a previously impaired CRE loan |
— |
— |
— |
2,332 |
||||||||||||
Loss on redemption of Series B Preferred Stock |
— |
— |
— |
7,482 |
||||||||||||
Litigation settlement expense |
— |
— |
— |
2,167 |
||||||||||||
Impairment on legacy CMBS investment |
— |
934 |
— |
934 |
||||||||||||
Core Earnings allocable to common shares, adjusted (5)(6)(7) |
$ |
7,349 |
$ |
7,477 |
$ |
33,963 |
$ |
22,342 |
||||||||
Weighted average common shares - diluted |
31,778 |
31,545 |
31,670 |
31,383 |
||||||||||||
Core Earnings per common share - diluted |
$ |
0.23 |
$ |
0.21 |
$ |
1.07 |
$ |
0.30 |
||||||||
Core Earnings per common share, adjusted - diluted (5)(6)(7) |
$ |
0.23 |
$ |
0.24 |
$ |
1.07 |
$ |
0.71 |
||||||||
(1) Income tax benefit from non-core investments and net realized gain on non-core assets are components of net income or loss from non-core assets. |
||||||||||||||||
(2) Non-core assets are investments and securities owned by XAN at the initial measurement date in (i) commercial finance, (ii) middle market lending, (iii) residential mortgage lending, (iv) legacy CRE assets and (v) other non-CRE assets included in assets held for sale. |
||||||||||||||||
(3) Includes realized gains of $70,000, or $0.00 per common share-diluted, and $352,000, or $0.01 per common share-diluted, in connection with the sale of CMBS for the three months and year ended December 31, 2018, respectively, and a realized recovery of CRE loan loss provision of $168,000, or $0.01 per common share-diluted, in connection with the sale of a previously impaired, 2013 vintage CRE loan for the year ended December 31, 2018. |
||||||||||||||||
(4) Reflects the payment of the settlement of a securities litigation, previously accrued in 2017, for the year ended December 31, 2018. |
||||||||||||||||
(5) Core Earnings, adjusted exclude a realized loss of $(2.3) million, or $(0.07) per common share-diluted, for the year ended December 31, 2018 in connection with the sale of a previously impaired, 2013 vintage CRE loan. |
||||||||||||||||
(6) Core Earnings, adjusted exclude a non-recurring charge of $(7.5) million, or $(0.24) per common share-diluted, for the year ended December 31, 2018 in connection with the redemption of the Company's 8.25% Series B Cumulative Redeemable Preferred Stock. |
||||||||||||||||
(7) Core Earnings, adjusted exclude an impairment charge of $(934,000), or $(0.03) per common share-diluted, for the three months and year ended December 31, 2018 in connection with a legacy CMBS investment. |
||||||||||||||||
SCHEDULE II
EXANTAS CAPITAL CORP. AND SUBSIDIARIES
SUMMARY OF SECURITIZATION PERFORMANCE STATISTICS
(unaudited)
Distributions, Coverage Tests and Liquidations
The following table sets forth the distributions received by XAN and coverage test summaries for its active securitizations for the periods presented (in thousands):
Cash Distributions For the Year Ended |
Overcollateralization Cushion (1) |
|||||||||||||||||
Name |
December 31, |
December 31, |
At December 31, |
At the Initial |
End of Designated |
|||||||||||||
XAN 2018-RSO6 (2) |
$ |
17,959 |
$ |
8,323 |
$ |
71,186 |
$ |
25,731 |
December 2020 |
|||||||||
XAN 2019-RSO7 (2) |
$ |
10,672 |
$ |
— |
$ |
34,356 |
$ |
34,341 |
April 2022 |
|||||||||
Apidos CDO I, Ltd. (3) |
$ |
708 |
$ |
— |
N/A |
$ |
17,136 |
N/A |
||||||||||
Apidos CDO III, Ltd. (3) |
$ |
— |
$ |
618 |
N/A |
$ |
11,269 |
N/A |
||||||||||
(1) Overcollateralization cushion represents the amount by which the collateral held by the securitization issuer exceeds the minimum amount required. |
||||||||||||||||||
(2) The designated principal reinvestment period for Exantas Capital Corp. 2018-RSO6, Ltd. and Exantas Capital Corp. 2019-RSO7, Ltd. is the period in which principal repayments can be utilized to purchase loans held outside of the respective securitization that represent the funded commitments of existing collateral in the respective securitization that were not funded as of the date the respective securitization was closed. Additionally, the indenture for each securitization does not contain any interest coverage test provisions. |
||||||||||||||||||
(3) Apidos CDO I, Ltd. and Apidos CDO III, Ltd. were substantially liquidated in October 2014 and June 2015, respectively. |
||||||||||||||||||
The following table sets forth the distributions received by XAN and liquidation details for its liquidated securitizations for the periods presented (in thousands):
Cash Distributions For the Year Ended |
Liquidation Details |
|||||||||||||
Name |
December 31, 2019 |
December 31, 2018 |
Liquidation Date |
Remaining |
||||||||||
RCC 2015-CRE3 |
$ |
— |
$ |
3,529 |
August 2018 |
$ |
80,632 |
|||||||
RCC 2015-CRE4 |
$ |
— |
$ |
4,487 |
July 2018 |
$ |
97,825 |
|||||||
RCC 2017-CRE5 |
$ |
12,551 |
$ |
22,843 |
July 2019 |
$ |
112,753 |
|||||||
Whitney CLO I, Ltd. (2) |
$ |
68 |
$ |
— |
January 2019 |
$ |
— |
|||||||
(1) The remaining assets at the liquidation date were distributed to XAN in exchange for its preference shares and equity notes in the securitization. |
||||||||||||||
(2) Whitney CLO I, Ltd. was substantially liquidated in September 2013. |
||||||||||||||
SCHEDULE III
EXANTAS CAPITAL CORP. AND SUBSIDIARIES
CRE LOAN ACTIVITIES
(unaudited)
The following table summarizes XAN's CRE loan activities and fundings of previous commitments for the periods then ended (in millions):
For the Three Months Ended |
||||||||||||||||||||
December 31, 2019 |
September 30, 2019 |
June 30, 2019 |
March 31, 2019 |
December 31, 2018 |
||||||||||||||||
New CRE loan commitments |
$ |
203.0 |
$ |
105.1 |
$ |
243.4 |
$ |
171.0 |
$ |
274.9 |
||||||||||
New CRE preferred equity investment |
— |
— |
8.7 |
— |
— |
|||||||||||||||
Total CRE loan commitments and investments |
203.0 |
105.1 |
252.1 |
171.0 |
274.9 |
|||||||||||||||
Payoffs and paydowns (1) |
(182.0) |
(256.8) |
(136.9) |
(67.4) |
(203.1) |
|||||||||||||||
Previous commitments funded |
10.8 |
7.9 |
11.3 |
13.0 |
13.3 |
|||||||||||||||
New unfunded loan commitments and investments |
(13.6) |
(12.0) |
(21.3) |
(6.3) |
(30.5) |
|||||||||||||||
Net CRE loans funded (repaid) |
18.2 |
(155.8) |
105.2 |
110.3 |
54.6 |
|||||||||||||||
Acquired CRE loans (committed balance) |
— |
— |
210.8 |
— |
— |
|||||||||||||||
Payoffs and paydowns |
(22.8) |
(0.1) |
(16.7) |
— |
— |
|||||||||||||||
Previous commitments funded |
— |
0.2 |
— |
— |
— |
|||||||||||||||
Acquired unfunded loan commitments |
— |
— |
(14.0) |
— |
— |
|||||||||||||||
Net CRE loans (repaid) acquired |
(22.8) |
0.1 |
180.1 |
— |
— |
|||||||||||||||
Net CRE loans (repaid) funded and acquired |
$ |
(4.6) |
$ |
(155.7) |
$ |
285.3 |
$ |
110.3 |
$ |
54.6 |
||||||||||
(1) Activity excludes legacy CRE loans (see Strategic Plan Update). |
||||||||||||||||||||
SCHEDULE IV
EXANTAS CAPITAL CORP. AND SUBSIDIARIES
ECONOMIC BOOK VALUE PER SHARE
(unaudited)
Management views economic book value, a non-GAAP measure, as a useful and appropriate supplement to GAAP stockholders' equity and common stock book value because it adjusts GAAP common stock book value to account for the face redemption amounts of the Company's outstanding preferred stock and convertible senior notes. The following table reconciles XAN's common stock book value per share to its economic book value per share at the dates presented:
At December 31, 2019 |
At September 30, 2019 |
At June 30, 2019 |
At March 31, 2019 |
At December 31, 2018 |
||||||||||||||||
Common stock book value |
$ |
14.00 |
$ |
14.12 |
$ |
14.06 |
$ |
14.06 |
$ |
14.02 |
||||||||||
Non-cash convertible senior notes' |
(0.26) |
(0.28) |
(0.30) |
(0.33) |
(0.35) |
|||||||||||||||
Preferred stock redemption value in excess of |
(0.13) |
(0.13) |
(0.13) |
(0.13) |
(0.13) |
|||||||||||||||
Economic book value |
$ |
13.61 |
$ |
13.71 |
$ |
13.63 |
$ |
13.60 |
$ |
13.54 |
||||||||||
SCHEDULE V
EXANTAS CAPITAL CORP. AND SUBSIDIARIES
SUPPLEMENTAL INFORMATION
Certain Loan Statistics
The following table presents information on XAN's allowance for CRE loan losses, which excludes fair value adjustments on a legacy CRE asset classified as assets held for sale, at the dates indicated (amounts in thousands, percentages based on amortized cost):
December 31, 2019 |
December 31, 2018 |
|||||||
(unaudited) |
||||||||
Allowance for loan losses: |
||||||||
General allowance: |
||||||||
CRE whole loans |
$ |
1,460 |
$ |
1,401 |
||||
Total general allowance |
1,460 |
1,401 |
||||||
Total allowance for loans |
$ |
1,460 |
$ |
1,401 |
||||
Allowance as a percentage of total loans |
0.1 |
% |
0.1 |
% |
||||
There was no specific allowance for loan losses at December 31, 2019 or 2018.
The following table presents unaudited CRE loan portfolio statistics at December 31, 2019 (percentages based on carrying value at December 31, 2019):
Loan type: |
||||
Whole loans |
98.3 |
% |
||
Preferred equity investments |
1.4 |
% |
||
Mezzanine loan |
0.3 |
% |
||
Total |
100.0 |
% |
||
Collateral type: |
||||
Multifamily |
57.5 |
% |
||
Office |
13.4 |
% |
||
Hotel |
10.5 |
% |
||
Retail |
7.9 |
% |
||
Self-Storage |
6.5 |
% |
||
Manufactured Housing |
3.5 |
% |
||
Industrial |
0.7 |
% |
||
Total |
100.0 |
% |
||
Collateral by NCREIF U.S. region: |
||||
Mountain (1) |
19.5 |
% |
||
Southwest (2) |
19.4 |
% |
||
Southeast (3) |
17.6 |
% |
||
Pacific (4) |
13.9 |
% |
||
Mid Atlantic (5) |
11.9 |
% |
||
Northeast (6) |
11.8 |
% |
||
East North Central |
5.3 |
% |
||
West North Central |
0.6 |
% |
||
Total |
100.0 |
% |
||
(1) CRE loans in Arizona and Nevada represent 9.0% and 7.1%, respectively, of the total loan portfolio. |
||||
(2) CRE loans in Texas represent 17.5% of the total loan portfolio. |
||||
(3) CRE loans in Florida and Georgia represent 10.5% and 6.4%, respectively, of the total loan portfolio. |
||||
(4) CRE loans in California represent 12.5% of the total loan portfolio. |
||||
(5) CRE loans in South Carolina represent 5.2% of the total loan portfolio. |
||||
(6) CRE loans in New York represent 6.3% of the total loan portfolio. |
||||
CONTACT: |
DAVID J. BRYANT |
CHIEF FINANCIAL OFFICER |
|
EXANTAS CAPITAL CORP. |
|
717 Fifth Avenue |
|
New York, NY 10022 |
|
212-621-3210 |
SOURCE Exantas Capital Corp.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article